HIV-1 entry inhibitors: Classes, applications and factors affecting potency

Current HIV Research

Volumn 4, Issue 4, 2006, Pages 387-400

  Sterjovski, Jasminka ^a,b   Churchill, Melissa J ^a,b   Wesselingh, Steve L ^a,b   Gorry, Paul R ^a,b,c  

^a MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Entry; HIV 1; Inhibitors; Resistance; Sensitivity

Indexed keywords

1 ACETYL N [3 [4 (4 CARBAMOYLBENZYL) 1 PIPERIDINYL]PROPYL] N (3 CHLORO 4 METHYLPHENYL) 4 PIPERIDINECARBOXAMIDE; 1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; AMD 070; AMD 3415; ANCRIVIROC; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; APLAVIROC; CADA; CD4 IMMUNOGLOBULIN G2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; ENFUVIRTIDE; FUSEON; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VICRIVIROC; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DISEASE COURSE; DRUG HALF LIFE; DRUG POTENCY; DRUG SYNTHESIS; HEART DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; VIRUS RESISTANCE; VIRUS STRAIN;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MEMBRANE FUSION; RECEPTORS, CCR5;

EID: 33749535051     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016206778560081     Document Type: Review

References (203)

1. Adkison KK, Shachoy-Clark A, Fang L, Lou Y, O'Mara K, Berrey MM, Piscitelli SC. (2005). Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects. Antimicrobial Agents and Chemotherapy. 49: 2802-2806.
2. Allaway GP, Davis-Bruno KL, Beaudry GA, Garcia EB, Wong EL, Ryder AM, Hasel KW, Gauduin MC, Koup RA, McDougal JS, Maddon JP. (1995). Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Research and Human Retroviruses. 11: 533-539.
3. An P, Martin MP, Nelson GW, Carrington M, Smith MW, Gong K, Vlahov D, O'Brien SJ, Winkler CA. (2000). Influence of CCR5 promoter haplotypes on AIDS progression in African-Americans. AIDS. 14:2117-2122.
4. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y, Meguro K, Fujino M. (1999). A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proceedings of the National Academy of Sciences of the United States of America. 96: 5698-5703.
5. Barber CG. (2004). CCR5 antagonists for the treatment of HIV. Current Opinion in Investigational Drugs. 5: 851-861.
6. Bjorndal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A, Albert J, Scarlatti G, Littman DR, Fenyo EM. (1997). Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. Journal of Virology. 71: 7478-7487.
7. Blanpain C, Lee B, Tackoen M, Puffer B, Boom A, Libert F, Sharron M, Wittamer V, Vassart G, Doms RW, Parmentier M. (2000). Multiple nonfunctional alleles of CCR5 are frequent in various human populations. Blood. 96: 1638-1645.
8. Blanpain C, Libert F, Vassart G, Parmentier M. (2002). CCR5 and HIV infection. Receptors and Channels. 8: 19-31.
9. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. (1997). The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America. 94: 1925-1930.
10. Burton DR, Stanfield RL, Wilson IA. (2005). Antibody vs. HIV in a clash of evolutionary titans. Proceedings of the National Academy of Sciences of the United States of America. 102: 14943-14948.
11. Campbell DJ, Kim CH, Butcher EC. (2003). Chemokines in the systemic organization of immunity. Immunology Reviews. 195: 58-71.
12. Chan DC, Fass D, Berger JM, Kim PS. (1997). Core structure of gp41 from the HIV envelope glycoprotein. Cell. 89: 263-273.
13. Chan DC, Chutkowski CT, Kim PS. (1998). Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proceedings of the National Academy of Sciences of the United States of America. 95: 15613-15617.
14. Cho MW, Lee MK, Carney MC, Berson JF, Doms RW, Martin MA. (1998). Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. Journal of Virology. 72: 2509-2515.
15. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, Sodroski J. (1996). The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 85: 1135-1148.
16. Choe H, Farzan M, Konkel M, Martin K, Sun Y, Marcon L, Cayabyab M, Berman M, Dorf ME, Gerard N, Gerard C, Sodroski J. (1998). The orphan seven-transmembrane receptor apj supports the entry of primary T-cell-line-tropic and dualtropic human immunodeficiency virus type 1. Journal of Virology. 72: 6113-6118.
17. Choudhary SK, Choudhary NR, Kimbrell KC, Colasanti J, Ziogas A, Kwa D, Schuitemaker H, Camerini D. (2005). R5 human immunodeficiency virus type 1 infection of fetal thymic organ culture induces cytokine and CCR5 expression. Journal of Virology. 79: 458-471.
18. Churchill M, Sterjovski J, Gray L, Cowley D, Chatfield C, Learmont J, Sullivan JS, Crowe SM, Mills J, Brew BJ, Wesselingh SL, McPhee DA, Gorry PR. (2004). Longitudinal analysis of nef/long terminal repeat-deleted HIV-1 in blood and cerebrospinal fluid of a long-term survivor who developed HIV-associated dementia. Journal of Infectious Diseases. 190: 2181-2186.
19. Combadiere B, Faure S, Autran B, Debre P, Combadiere C. (2003). The chemokine receptor CX3CR1 controls homing and anti-viral potencies of CD8 effector-memory T lymphocytes in HIV-infected patients. AIDS. 17: 1279-1290.
20. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. (1997). Change in coreceptor use coreceptor use correlates with disease progression in HIV-1 - infected individuals. Journal of Experimental Medicine. 185: 621-628.
21. Crowe SM, Sonza S. (2000). HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy: a further obstacle to eradication. Journal of Leukocyte Biology. 68: 345-350.
22. Dalgleish AG BP, Clapham PR, Crawford DH, Greaves MF, Weiss RA. (1984). The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 312: 763-767.
23. De Clercq E, Yamamoto N, Pauwels R, Balzarini J, Witvrouw M, De Vreese K, Debyser Z, Rosenwirth B, Peichl P, Datema R, Thornton D, Skerlj R, Gaul F, Padmanabhan S, Bridger G, Henson G, Abrams M. (1994). Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrobial Agents and Chemotherapy. 38: 668-674.
24. De Clercq E. (2004). HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches. International Journal of Biochemistry and Cell Biology. 36: 1800-1822.
25. de Roda Husman AM, Schuitemaker H. (1998). Chemokine receptors and the clinical course of HIV-1 infection. Trends in Microbiology. 6: 244-249.
26. Deen KC, McDougal JS, Inacker R, Folena-Wasserman G, Arthos J, Rosenberg J, Maddon PJ, Axel R, Sweet RW. (1988). A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature. 331: 82-84.
27. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. (1996). Identification of a major co-receptor for primary isolates of HIV-1. Nature. 381: 661-666.
28. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, Kappes JC, Shaw GM, Hunter E. (2000). Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. Journal of Virology. 74: 8358-8367.
29. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RG, Doms RW. (1996). A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell. 85: 1149-1158.
30. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A, Perros M. (2005). Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrobial Agents and Chemotherapy. 49: 4721-4732.
31. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA. (1996). HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 381: 667-673.
32. Dragic T, Trkola A, Lin SW, Nagashima KA, Kajumo F, Zhao L, Olson WC, Wu L, Mackay CR, Allaway GP, Sakmar TP, Moore JP, Maddon PJ. (1998). Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. Journal of Virology. 72: 279-285.
33. Dragic T, Trkola A, Thompson DA, Cormier EG, Kajumo FA, Maxwell E, Lin SW, Ying W, Smith SO, Sakmar TP, Moore JP. (2000). A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proceedings of the National Academy of Sciences of the United States of America. 97: 5639-5644.
34. Dwyer JJ, Hasan A, Wilson KL, White JM, Matthews TJ, Delmedico MK. (2003). The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation. Biochemistry. 42: 4945-4953.
35. Eckert DM, Kim PS. (2001). Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proceedings of the National Academy of Sciences of the United States of America. 98: 11187-11192.
36. Edinger AL, Hoffman TL, Sharron M, Lee B, O'Dowd B, Doms RW. (1998). Use of GPR1, GPR15, and STRL33 as coreceptors by diverse human immunodeficiency virus type 1 and simian immunodeficiency virus envelope proteins. Virology. 249: 367-378.
37. Eron JJ, Gulick RM, Bartlett JA, Merigan T, Arduino R, Kilby JM, Yangco B, Diers A, Drobnes C, DeMasi R, Greenberg M, Melby T, Raskino C, Rusnak P, Zhang Y, Spence R, Miralles GD. (2004). Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. Journal of Infectious Diseases. 189: 1075-1083.
38. Este JA, Cabrera C, Blanco J, Gutierrez A, Bridger G, Henson G, Clotet B, Schols D, De Clercq E. (1999). Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. Journal of Virology. 73: 5577-5585.
39. Farber JM, Berger EA. (2002). HIV's response to a CCR5 inhibitor: I'd rather tighten than switch! Proceedings of the National Academy of Sciences of the United States of America. 99: 1749-1751.
40. Farzan M, Mirzabekov T, Kolchinsky P, Wyatt R, Cayabyab M, Gerard NP, Gerard C, Sodroski J, Choe H. (1999). Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell. 96: 667-676.
41. Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, Saag MS, Goebel FD, Rockstroh JK, Dezube BJ, Jenkins TM, Medhurst C, Sullivan JF, Ridgway C, Abel S, James IT, Youle M, van der Ryst E. (2005). Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nature Medicine. 11: 1170-1172.
42. Feng Y, Broder CC, Kennedy PE, Berger EA. (1996). HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 272: 872-877.
43. Fenyo EM, Fiore J, Karlsson A, Albert J, Scarlatti G. (1994). Biological phenotypes of HIV-1 in pathogenesis and transmission. Antibiotics and Chemotherapy. 46: 18-24.
44. Fisher RA, Bertonis JM, Meier W, Johnson VA, Costopoulos DS, Liu T, Tizard R, Walker BD, Hirsch MS, Schooley RT, Flavell RA. (1988). HIV infection is blocked in vitro by recombinant soluble CD4. Nature. 331: 76-78.
45. Freed EO, Risser R. (1991). Identification of conserved residues in the human immunodeficiency virus type 1 principal neutralizing determinant that are involved in fusion. AIDS Research and Human Retroviruses. 7: 807-811.
46. Furuta RA, Wild CT, Weng Y, Weiss CD. (1998). Capture of an early fusion-active conformation of HIV-1 gp41. Nature Structural and Molecular Biology. 5: 276-279.
47. Glushakova S, Baibakov B, Margolis LB, Zimmerberg J. (1995). Infection of human tonsil histocultures: a model for HIV pathogenesis. Nature Medicine. 1: 1320-1322.
48. Gorry PR, Bristol G, Zack JA, Ritola K, Swanstrom R, Birch CJ, Bell JE, Bannert N, Crawford K, Wang H, Schols D, De Clercq E, Kunstman K, Wolinsky SM, Gabuzda D. (2001). Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. Journal of Virology. 75: 10073-10089.
49. Gorry PR, Taylor J, Holm GH, Mehle A, Morgan T, Cayabyab M, Farzan M, Wang H, Bell JE, Kunstman K, Moore JP, Wolinsky SM, Gabuzda D. (2002). Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. Journal of Virology. 76: 6277-6292.
50. Gorry PR, Churchill M, Crowe SM, Cunningham AL, Gabuzda D. (2005). Pathogenesis of macrophage tropic HIV-1. Current HIV Research. 3: 53-60.
51. Gray L, Sterjovski J, Churchill M, Ellery P, Nasr N, Lewin SR, Crowe SM, Wesselingh SL, Cunningham AL, Gorry PR. (2005). Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome. Virology. 337: 384-398.
52. Greenberg ML, Cammack N. (2004). Resistance to enfuvirtide, the first HIV fusion inhibitor. Journal of Antimicrobial Chemotherapy. 54: 333-340.
53. Grivel JC, Margolis LB. (1999). CCR5- and CXCR4-tropic HIV-1 are equally cytopathic for their T-cell targets in human lymphoid tissue. Nature Medicine. 5: 344-346.
54. Grundner C, Pancera M, Kang JM, Koch M, Sodroski J, Wyatt R. (2004). Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins. Virology. 330: 233-248.
55. Guo Q, Ho HT, Dicker I, Fan L, Zhou N, Friborg J, Wang T, McAuliffe BV, Wang HG, Rose RE, Fang H, Scarnati HT, Langley DR, Meanwell NA, Abraham R, Colonno RJ, Lin PF. (2003). Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. Journal of Virology. 77: 10528-10536.
56. Hartley O, Gaertner H, Wilken J, Thompson D, Fish R, Ramos A, Pastore C, Dufour B, Cerini F, Melotti A, Heveker N, Picard L, Alizon M, Mosier D, Kent S, Offord R. (2004). Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 101: 16460-16465.
57. Heil ML, Decker JM, Sfakianos JN, Shaw GM, Hunter E, Derdeyn CA. (2004). Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site. Journal of Virology. 78: 7582-7589.
58. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E, Bridger G, Henson GW. (2000). Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrobial Agents and Chemotherapy. 44: 1667-1673.
59. Hoffman NG, Seillier-Moiseiwitsch F, Ahn J, Walker JM, Swanstrom R. (2002). Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. Journal of Virology. 76: 3852-3864.
60. Hoffman TL, Doms RW. (1998). Chemokines and coreceptors in HIV/SIV-host interactions. AIDS. 12 (Suppl A): S17-26.
61. Hoffman TL, Stephens EB, Narayan O, Doms RW. (1998). HIV type I envelope determinants for use of the CCR2b, CCR3, STRL33, and APJ coreceptors. Proceedings of the National Academy of Sciences of the United States of America. 95: 11360-11365.
62. Hoffman TL, Doms RW. (1999). HIV-1 envelope determinants for cell tropism and chemokine receptor use. Molecular Membrane Biology. 16: 57-65.
63. Hoffman TL, LaBranche CC, Zhang W, Canziani G, Robinson J, Chaiken I, Hoxie JA, Doms RW. (1999). Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proceedings of the National Academy of Sciences of the United States of America. 96: 6359-6364.
64. Holm GH, Zhang C, Gorry PR, Peden K, Schols D, De Clercq E, Gabuzda D. (2004). Apoptosis of bystander T cells induced by human immunodeficiency virus type 1 with increased envelope/receptor affinity and coreceptor binding site exposure. Journal of Virology. 78: 4541-4551.
65. Horuk R, Hesselgesser J, Zhou Y, Faulds D, Halks-Miller M, Harvey S, Taub D, Samson M, Parmentier M, Rucker J, Doranz BJ, Doms RW. (1998). The CC chemokine I-309 inhibits CCR8-dependent infection by diverse HIV-1 strains. Journal of Biological Chemistry. 273: 386-391.
66. Hu Q, Frank I, Williams V, Santos JJ, Watts P, Griffin GE, Moore JP, Pope M, Shattock RJ. (2004). Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. Journal of Experimental Medicine. 199: 1065-1075.
67. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh K, Kunstman K, Erickson D, Dragon E, Landau NR, Phair J, Ho DD, Koup RA. (1996). The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Medicine. 2: 1240-1243.
68. Jacobson JM, Lowy I, Fletcher CV, O'Neill TJ, Tran DN, Ketas TJ, Trkola A, Klotman ME, Maddon PJ, Olson WC, Israel RJ. (2000). Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. Journal of Infectious Diseases. 182: 326-329.
69. Jacobson JM, Israel RJ, Lowy I, Ostrow NA, Vassilatos LS, Barish M, Tran DN, Sullivan BM, Ketas TJ, O'Neill TJ, Nagashima KA, Huang W, Petropoulos CJ, Moore JP, Maddon PJ, Olson WC. (2004). Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrobial Agents and Chemotherapy. 48: 423-429.
70. Jansson M, Popovic M, Karlsson A, Cocchi F, Rossi P, Albert J, Wigzell H. (1996). Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates. Proceedings of the National Academy of Sciences of the United States of America. 93: 15382-15387.
71. Jansson M, Backstrom E, Bjorndal A, Holmberg V, Rossi P, Fenyo EM, Popovic M, Albert J, Wigzell H. (1999). Coreceptor usage and RANTES sensitivity of non-syncytium-inducing HIV-1 isolates obtained from patients with AIDS. Journal of Human Virology. 2: 325-338.
72. Ji H, Shu W, Burling FT, Jiang S, Lu M. (1999). Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion. Journal of Virology. 73: 8578-8586.
73. Jinno A, Shimizu N, Soda Y, Haraguchi Y, Kitamura T, Hoshino H. (1998). Identification of the chemokine receptor TER1/CCR8 expressed in brain-derived cells and T cells as a new coreceptor for HIV-1 infection. Biochemical and Biophysical Research Communications. 243: 497-502.
74. Kang SM, Quan FS, Huang C, Guo L, Ye L, Yang C, Compans RW. (2005). Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies. Virology. 331: 20-32.
75. Karlsson A, Parsmyr K, Sandstrom E, Fenyo EM, Albert J. (1994). MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. Journal of Clinical Microbiology. 32: 364-370.
76. Karlsson I, Antonsson L, Shi Y, Oberg M, Karlsson A, Albert J, Olde B, Owman C, Jansson M, Fenyo EM. (2004). Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype. Journal of Virology. 78: 11807-11815.
77. Kawamura T, Bruse SE, Abraha A, Sugaya M, Hartley O, Offord RE, Arts EJ, Zimmerman PA, Blauvelt A. (2004). PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes. Journal of Virology. 78: 7602-7609.
78. Kazmierski W, Bifulco N, Yang H, Boone L, DeAnda F, Watson C, Kenakin T. (2003). Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors. Bioorganic and Medicinal Chemistry. 11: 2663-2676.
79. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, Saag MS. (1998). Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Medicine. 4: 1302-1307.
80. Kimata JT. (2006). HIV-1 fitness and disease progression: insights from the SIV-macaque model. Current HIV Research. 4: 65-77.
81. Koch M, Pancera M, Kwong PD, Kolchinsky P, Grundner C, Wang L, Hendrickson WA, Sodroski J, Wyatt R. (2003). Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology. 313: 387-400.
82. Kolchinsky P, Mirzabekov T, Farzan M, Kiprilov E, Cayabyab M, Mooney LJ, Choe H, Sodroski J. (1999). Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication. Journal of Virology. 73: 8120-8126.
83. Kolchinsky P, Kiprilov E, Bartley P, Rubinstein R, Sodroski J. (2001). Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. Journal of Virology. 75: 3435-3443.
84. Koning FA, Kwa D, Boeser-Nunnink B, Dekker J, Vingerhoed J, Hiemstra H, Schuitemaker H. (2003). Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and - secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. Journal of Infectious Diseases. 188: 864-872.
85. Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, Coutinho RA, Miedema F, Schellekens PT, Tersmette M. (1993). Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Annals of Internal Medicine. 118: 681-688.
86. Koshiba T, Chan DC. (2003). The prefusogenic intermediate of HIV-1 gp41 contains exposed C-peptide regions. Journal of Biological Chemistry. 278: 7573-7579.
87. Kowalski M, Potz J, Basiripour L, Dorfman T, Goh WC, Terwilliger E, Dayton A, Rosen C, Haseltine W, Sodroski J. (1987). Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science. 237: 1351-1355.
88. Kozarsky K, Penman M, Basiripour L, Haseltine W, Sodroski J, Krieger M. (1989). Glycosylation and processing of the human immunodeficiency virus type 1 envelope protein. Journal of Acquired Immune Deficiency Syndromes. 2: 163-169.
89. Kwa D, Vingerhoed J, Boeser B, Schuitemaker H. (2003). Increased in vitro cytopathicity of CC chemokine receptor 5-restricted human immunodeficiency virus type 1 primary isolates correlates with a progressive clinical course of infection. Journal of Infectious Diseases. 187: 1397-1403.
90. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. (1998). Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 393: 648-659.
91. Kwong PD, Wyatt R, Majeed S, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. (2000). Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure with Folding and Design. 8: 1329-1339.
92. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, Steenbeke TD, Venturi M, Chaiken I, Fung M, Katinger H, Parren PW, Robinson J, Van Ryk D, Wang L, Burton DR, Freire E, Wyatt R, Sodroski J, Hendrickson WA, Arthos J. (2002). HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature. 420: 678-682.
93. Lalezari J, Thompson M, Kumar P, Piliero P, Davey R, Patterson K, Shachoy-Clark A, Adkison K, Demarest J, Lou Y, Berrey M, Piscitelli S. (2005). Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS. 19: 1443-1448.
94. Lapenta C, Parlato S, Spada M, Santini SM, Rizza P, Logozzi M, Proietti E, Belardelli F, Fais S. (1998). Human lymphoblastoid CD4(+) T cells become permissive to macrophage-tropic strains of human immunodeficiency virus type 1 after passage into severe combined immunodeficient mice through in vivo upregulation of CCR5: in vivo dynamics of CD4(+) T-cell differentiation in pathogenesis of AIDS. Journal of Virology. 72: 10323-10327.
95. Lederman MM, Veazey RS, Offord R, Mosier DE, Dufour J, Mefford M, Piatak M, Jr., Lifson JD, Salkowitz JR, Rodriguez B, Blauvelt A, Hartley O. (2004). Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science. 306: 485-487.
96. Lee B, Ratajczak J, Doms RW, Gewirtz AM, Ratajczak MZ. (1999). Coreceptor/chemokine receptor expression on human hematopoietic cells: biological implications for human immunodeficiency virus-type 1 infection. Blood. 93: 1145-1156.
97. Li S, Juarez J, Alali M, Dwyer D, Collman R, Cunningham A, Naif HM. (1999). Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates. Journal of Virology. 73: 9741-9755.
98. Lin PF, Blair W, Wang T, Spicer T, Guo Q, Zhou N, Gong YF, Wang HG, Rose R, Yamanaka G, Robinson B, Li CB, Fridell R, Deminie C, Demers G, Yang Z, Zadjura L, Meanwell N, Colonno R. (2003). A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proceedings of the National Academy of Sciences of the United States of America. 100: 11013-11018.
99. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR. (1996). Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 86: 367-377.
100. Louis JM, Bewley CA, Clore GM. (2001). Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity. Journal of Biological Chemistry. 276: 29485-29489.
101. Lu M, Blacklow SC, Kim PS. (1995). A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nature Structural and Molecular Biology. 2: 1075-1082.
102. Mack M, Luckow B, Nelson PJ, Cihak J, Simmons G, Clapham PR, Signoret N, Marsh M, Stangassinger M, Borlat F, Wells TN, Schlondorff D, Proudfoot AE. (1998). Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. Journal of Experimental Medicine. 187: 1215-1224.
103. Madani N, Perdigoto AL, Srinivasan K, Cox JM, Chruma JJ, LaLonde J, Head M, Smith AB, 3rd, Sodroski JG. (2004). Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. Journal of Virology. 78: 3742-3752.
104. Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, Shibayama S, Sagawa K, Fukushima D, Moravek J, Koyanagi Y, Mitsuya H. (2004). Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/ CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. Journal of Virology. 78: 8654-8662.
105. Marozsan AJ, Torre VS, Johnson M, Ball SC, Cross JV, Templeton DJ, Quinones-Mateu ME, Offord RE, Arts EJ. (2001). Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES. Journal of Virology. 75: 8624-8638.
106. Martin-Garcia J, Cao W, Varela-Rohena A, Plassmeyer ML, Gonzalez-Scarano F. (2006). HIV-1 tropism for the central nervous system: Brain-derived envelope glycoproteins with lower CD4 dependence and reduced sensitivity to a fusion inhibitor. Virology. 346: 169-179.
107. McCaffrey RA, Saunders C, Hensel M, Stamatatos L. (2004). N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. Journal of Virology. 78: 3279-3295.
108. Melikyan GB, Markosyan RM, Hemmati H, Delmedico MK, Lambert DM, Cohen FS. (2000). Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. Journal of Cell Biology. 151: 413-423.
109. Michael NL, Louie LG, Rohrbaugh AL, Schultz KA, Dayhoff DE, Wang CE, Sheppard HW. (1997). The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nature Medicine. 3: 1160-1162.
110. Milich L, Margolin BH, Swanstrom R. (1997). Patterns of amino acid variability in NSI-like and SI-like V3 sequences and a linked change in the CD4-binding domain of the HIV-1 Env protein. Virology. 239: 108-118.
111. Miller MD, Hazuda DJ. (2004). HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications. Drug Resistance Updates. 7: 89-95.
112. Moore JP, Cao Y, Qing L, Sattentau QJ, Pyati J, Koduri R, Robinson J, Barbas CF, 3rd, Burton DR, Ho DD. (1995). Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. Journal of Virology. 69: 101-109.
113. Moore JP, Ho DD. (1995). HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS. 9 Suppl A: S117-136.
114. Moore JP, Doms RW. (2003). The entry of entry inhibitors: a fusion of science and medicine. Proceedings of the National Academy of Sciences of the United States of America. 100: 10598-10602.
115. Moore PL, Cilliers T, Morris L. (2004). Predicted genotypic resistance to the novel entry inhibitor, BMS-378806, among HIV-1 isolates of subtypes A to G. AIDS. 18: 2327-2330.
116. Mosier DE, Picchio GR, Gulizia RJ, Sabbe R, Poignard P, Picard L, Offord RE, Thompson DA, Wilken J. (1999). Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. Journal of Virology. 73: 3544-3550.
117. Nagasawa T, Tachibana K, Kishimoto T. (1998). A novel CXC chemokine PBSF/ SDF-1 and its receptor CXCR4: their functions in development, hematopoiesis and HIV infection. Seminars in Immunology. 10: 179-185.
118. Nakata H, Maeda K, Miyakawa T, Shibayama S, Matsuo M, Takaoka Y, Ito M, Koyanagi Y, Mitsuya H. (2005). Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model. Journal of Virology. 79: 2087-2096.
119. Nishikawa M, Takashima K, Nishi T, Furuta RA, Kanzaki N, Yamamoto Y, Fujisawa J. (2005). Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5. Antimicrobial Agents and Chemotherapy. 49: 4708-4715.
120. O'Brien SJ, Moore JP. (2000). The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunology Reviews. 177: 99-111.
121. Ohagen A, Devitt A, Kunstman KJ, Gorry PR, Rose PP, Korber B, Taylor J, Levy R, Murphy RL, Wolinsky SM, Gabuzda D. (2003). Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. Journal of Virology. 77: 12336-12345.
122. Olsson J, Poles M, Spetz AL, Elliott J, Hultin L, Giorgi J, Andersson J, Anton P. (2000). Human immunodeficiency virus type 1 infection is associated with significant mucosal inflammation characterized by increased expression of CCR5, CXCR4, and beta-chemokines. Journal of Infectious Diseases. 182: 1625-1635.
123. Orloff SL, Kennedy MS, Belperron AA, Maddon PJ, McDougal JS. (1993). Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4. Journal of Virology. 67: 1461-1471.
124. Pantophlet R, Burton DR. (2006). GP120: Target for Neutralizing HIV-1 Antibodies. Annual Review of Immunology. 24: 739-69.
125. Parren PW, Moore JP, Burton DR, Sattentau QJ. (1999). The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS. 13(Suppl A): S137-162.
126. Pastore C, Picchio GR, Galimi F, Fish R, Hartley O, Offord RE, Mosier DE. (2003). Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES. Antimicrobial Agents and Chemotherapy. 47: 509-517.
127. Pastore C, Ramos A, Mosier DE. (2004). Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. Journal of Virology. 78: 7565-7574.
128. Pastore C, Nedellec R, Ramos A, Pontow S, Ratner L, Mosier DE. (2006).
129. Peters PJ, Bhattacharya J, Hibbitts S, Dittmar MT, Simmons G, Bell J, Simmonds P, Clapham PR. (2004). Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages. Journal of Virology. 78: 6915-6926.
130. Picchio GR, Gulizia RJ, Wehrly K, Chesebro B, Mosier DE. (1998). The cell tropism of human immunodeficiency virus type 1 determines the kinetics of plasma viremia in SCID mice reconstituted with human peripheral blood leukocytes. Journal of Virology. 72: 2002-2009.
131. Pierson T, Hoffman TL, Blankson J, Finzi D, Chadwick K, Margolick JB, Buck C, Siliciano JD, Doms RW, Siliciano RE. (2000). Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. Journal of Virology. 74: 7824-7833.
132. Pierson T, McArthur J, Siliciano RE. (2000). Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annual Review of Immunology. 18: 665-708.
133. Platt EJ, Kuhmann SE, Rose PP, Kabat D. (2001). Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region. Journal of Virology. 75: 12266-12278.
134. Platt EJ, Durnin JP, Kabat D. (2005). Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. Journal of Virology. 79: 4347-4356.
135. Platt EJ, Shea DM, Rose PP, Kabat D. (2005). Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan. Journal of Virology. 79: 4357-4368.
136. Princen K, Hatse S, Vermeire K, Aquaro S, De Clercq E, Gerlach LO, Rosenkilde M, Schwartz TW, Skerlj R, Bridger G, Schols D. (2004). Inhibition of human immunodeficiency virus replication by a dual CCR5/ CXCR4 antagonist. Journal of Virology. 78: 12996-13006.
137. Princen K, Schols D. (2005). HIV chemokine receptor inhibitors as novel anti-HIV drugs. Cytokine and Growth Factor Reviews. 16: 659-677.
138. Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, Pohlmann S, Sfakianos JN, Derdeyn CA, Blumenthal R, Hunter E, Doms RW. (2002). Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proceedings of the National Academy of Sciences of the United States of America. 99: 16249-16254.
139. Reeves JD, Miamidian JL, Biscone MJ, Lee FH, Ahmad N, Pierson TC, Doms RW. (2004). Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity. Journal of Virology. 78: 5476-5485.
140. Reitter JN, Means RE, Desrosiers RC. (1998). A role for carbohydrates in immune evasion in AIDS. Nature Medicine. 4: 679-684.
141. Repits J, Oberg M, Esbjornsson J, Medstrand P, Karlsson A, Albert J, Fenyo EM, Jansson M. (2005). Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. Journal of General Virology. 86: 2859-2869.
142. Reynes J, Portales P, Segondy M, Baillat V, Andre P, Avinens O, Picot MC, Clot J, Eliaou JF, Corbeau P. (2001). CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression. AIDS. 15: 1627-1634.
143. Richman DD. (2001). HIV chemotherapy. Nature. 410: 995-1001.
144. Richman DD, Wrin T, Little SJ, Petropoulos CJ. (2003). Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proceedings of the National Academy of Sciences of the United States of America. 100: 4144-4149.
145. Rimsky LT, Shugars DC, Matthews TJ. (1998). Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. Journal of Virology. 72: 986-993.
146. Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, Hendrickson WA, Sodroski J. (1998). A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science. 280: 1949-1953.
147. Root MJ, Kay MS, Kim PS. (2001). Protein design of an HIV-1 entry inhibitor. Science. 291: 884-888.
148. Root MJ, Hamer DH. (2003). Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein. Proceedings of the National Academy of Sciences of the United States of America. 100: 5016-5021.
149. Root MJ, Steger HK. (2004). HIV-1 gp41 as a target for viral entry inhibition. Current Pharmaceutical Design. 10: 1805-1825.
150. Rucker J, Edinger AL, Sharron M, Samson M, Lee B, Berson JF, Yi Y, Margulies B, Collman RG, Doranz BJ, Parmentier M, Doms RW. (1997). Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. Journal of Virology. 71: 8999-9007.
151. Rusconi S, Merrill DP, La Seta-Catamancio S, Citterio P, Offord RE, Hirsch MS. (1999). Effective inhibition of HIV-1 isolated from patients with acute primary HIV-1 infection by aminooxypentane-RANTES. AIDS. 13: 1144-1145.
152. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M. (1996). Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 382: 722-725.
153. Samson M, Edinger AL, Stordeur P, Rucker J, Verhasselt V, Sharron M, Govaerts C, Mollereau C, Vassart G, Doms RW, Parmentier M. (1998). ChemR23, a putative chemoattractant receptor, is expressed in monocyte-derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV-1 strains. European Journal of Immunology. 28: 1689-1700.
154. Sattentau Q. (1998). HIV gp120: double lock strategy foils host defences. Structure. 6: 945-949.
155. Sattentau QJ, Moore JP. (1991). Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. Journal of Experimental Medicine. 174: 407-415.
156. Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, Deng HK, Malnati MS, Plebani A, Siccardi AG, Littman DR, Fenyo EM, Lusso P. (1997). In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nature Medicine. 3: 1259-1265.
157. Schooley RT, Merigan TC, Gaut P, Hirsch MS, Holodniy M, Flynn T, Liu S, Byington RE, Henochowicz S, Gubish E, et al. (1990). Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Annals of Internal Medicine. 112: 247-253.
158. Schrager LK, D'Souza MP. (1998). Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. Journal of the American Medical Association. 280: 67-71.
159. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP, Lange JM, Schattenkerk JK, Miedema F, Tersmette M. (1992). Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. Journal of Virology. 66: 1354-1360.
160. Scoggins RM, Taylor JR, Jr., Patrie J, van't Wout AB, Schuitemaker H, Camerini D. (2000). Pathogenesis of primary R5 human immunodeficiency virus type 1 clones in SCID-hu mice. Journal of Virology. 74: 3205-3216.
161. Shiraishi M, Aramaki Y, Seto M, Imoto H, Nishikawa Y, Kanzaki N, Okamoto M, Sawada H, Nishimura O, Baba M, Fujino M. (2000). Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. Journal of Medicinal Chemistry. 43: 2049-2063.
162. Si Z, Madani N, Cox JM, Chruma JJ, Klein JC, Schon A, Phan N, Wang L, Biorn AC, Cocklin S, Chaiken I, Freire E, Smith AB, 3rd, Sodroski JG. (2004). Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proceedings of the National Academy of Sciences of the United States of America. 101: 5036-5041.
163. Signoret N, Pelchen-Matthews A, Mack M, Proudfoot AE, Marsh M. (2000). Endocytosis and recycling of the HIV coreceptor CCR5. Journal of Cell Biology. 151: 1281-1294.
164. Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schwartz TW, Buser R, Wells TN, Proudfoot AE. (1997). Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science. 276: 276-279.
165. Smith DH, Byrn RA, Marsters SA, Gregory T, Groopman JE, Capon DJ. (1987). Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science. 238: 1704-1707.
166. Sonza S, Crowe SM. (2001). Reservoirs for HIV infection and their persistence in the face of undetectable viral load. AIDS Patient Care and STDs. 15: 511-518.
167. Strizki JM, Xu S, Wagner NE, Wojcik L, Liu J, Hou Y, Endres M, Palani A, Shapiro S, Clader JW, Greenlee WJ, Tagat JR, McCombie S, Cox K, Fawzi AB, Chou CC, Pugliese-Sivo C, Davies L, Moreno ME, Ho DD, Trkola A, Stoddart CA, Moore JP, Reyes GR, Baroudy BM. (2001). SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America. 98: 12718-12723.
168. Strizki JM, Tremblay C, Xu S, Wojcik L, Wagner N, Gonsiorek W, Hipkin RW, Chou CC, Pugliese-Sivo C, Xiao Y, Tagat JR, Cox K, Priestley T, Sorota S, Huang W, Hirsch M, Reyes GR, Baroudy BM. (2005). Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy. 49: 4911-4919.
169. Suntoke TR, Chan DC. (2005). The fusion activity of HIV-1 gp41 depends on interhelical interactions. Journal of Biological Chemistry. 280: 19852-19857.
170. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, Kitamura Y, Matsushima K, Yoshida N, Nishikawa S, Kishimoto T, Nagasawa T. (1998). The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature. 393: 591-594.
171. Tagat JR, McCombie SW, Nazareno D, Labroli MA, Xiao Y, Steensma RW, Strizki JM, Baroudy BM, Cox K, Lachowicz J, Varty G, Watkins R. (2004). Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl) phenyl]ethyl-3(S)-methyl-1-piperaz inyl]- 4-methylpiperidine (Sch-417690/ Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. Journal of Medicinal Chemistry. 47: 2405-2408.
172. Takashima K, Miyake H, Kanzaki N, Tagawa Y, Wang X, Sugihara Y, Iizawa Y, Baba M. (2005). Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist. Antimicrobial Agents and Chemotherapy. 49: 3474-3482.
173. Tersmette M, Gruters RA, de Wolf F, de Goede RE, Lange JM, Schellekens PT, Goudsmit J, Huisman HG, Miedema F. (1989). Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. Journal of Virology. 63: 2118-2125.
174. Thompson KA, Churchill MJ, Gorry PR, Sterjovski J, Oelrichs RB, Wesselingh SL, McLean CA. (2004). Astrocyte specific viral strains in HIV dementia. Annals of Neurology. 56: 873-877.
175. Toossi Z, Mayanja-Kizza H, Baseke J, Peters P, Wu M, Abraha A, Aung H, Okwera A, Hirsch C, Arts E. (2005). Inhibition of human immunodeficiency virus-1 (HIV-1) by beta-chemokine analogues in mononuclear cells from HIV-1-infected patients with active tuberculosis. Clinical and Experimental Immunology. 142: 327-332.
176. Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, Allaway GP, Katinger H, Barbas CF, 3rd, Burton DR, Ho DD, Moore JP. (1995). Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. Journal of Virology. 69: 6609-6617.
177. Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, Pugach P, Xu S, Wojcik L, Tagat J, Palani A, Shapiro S, Clader JW, McCombie S, Reyes GR, Baroudy BM, Moore JP. (2002). HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proceedings of the National Academy of Sciences of the United States of America. 99: 395-400.
178. Tuttle DL, Anders CB, Aquino-De Jesus MJ, Poole PP, Lamers SL, Briggs DR, Pomeroy SM, Alexander L, Peden KW, Andiman WA, Sleasman JW, Goodenow MM. (2002). Increased replication of non-syncytium-inducing HIV type 1 isolates in monocyte-derived macrophages is linked to advanced disease in infected children. AIDS Research and Human Retroviruses. 18: 353-362.
179. van't Wout AB, Kootstra NA, Mulder-Kampinga GA, Albrecht-van Lent N, Scherpbier HJ, Veenstra J, Boer K, Coutinho RA, Miedema F, Schuitemaker H. (1994). Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. The Journal of Clinical Investigation. 94: 2060-2067.
180. Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, Hu Q, Ketas T, Marx PA, Klasse PJ, Burton DR, Moore JP. (2003). Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nature Medicine. 9: 343-346.
181. Veazey RS, Klasse PJ, Schader SM, Hu Q, Ketas TJ, Lu M, Marx PA, Dufour J, Colonno RJ, Shattock RJ, Springer MS, Moore JP. (2005). Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature. 438: 99-102.
182. Vermeire K, Zhang Y, Princen K, Hatse S, Samala MF, Dey K, Choi HJ, Ahn Y, Sodoma A, Snoeck R, Andrei G, De Clercq E, Bell TW, Schols D. (2002). CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor. Virology. 302: 342-353.
183. Vermeire K, Bell TW, Choi HJ, Jin Q, Samala MF, Sodoma A, De Clercq E, Schols D. (2003). The Anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor. Molecular Pharmacology. 63: 203-210.
184. Vermeire K, Princen K, Hatse S, De Clercq E, Dey K, Bell TW, Schols D. (2004). CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. AIDS. 18: 2115-2125.
185. Vermeire K, Schols D. (2005). Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor. Expert Opinion on Investigational Drugs. 14: 1199-1212.
186. Vermeire K, Schols D. (2005). Cyclotriazadisulfonamides: promising new CD4-targeted anti-HIV drugs. Journal of Antimicrobial Chemotherapy. 56: 270-272.
187. Wahl SM, Greenwell-Wild T, Hale-Donze H, Moutsopoulos N, Orenstein JM. (2000). Permissive factors for HIV-1 infection of macrophages. Journal of Leukocyte Biology. 68: 303-310.
188. Wang HG, Williams RE, Lin PF. (2004). A novel class of HIV-1 inhibitors that targets the viral envelope and inhibits CD4 receptor binding. Current Pharmaceutical Design. 10: 1785-1793.
189. Wang T, Zhang Z, Wallace OB, Deshpande M, Fang H, Yang Z, Zadjura LM, Tweedie DL, Huang S, Zhao F, Ranadive S, Robinson BS, Gong YF, Ricarrdi K, Spicer TP, Deminie C, Rose R, Wang HG, Blair WS, Shi PY, Lin PF, Colonno RJ, Meanwell NA. (2003). Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. Journal of Medicinal Chemistry. 46: 4236-4239.
190. Watson C, Jenkinson S, Kazmierski W, Kenakin T. (2005). The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Molecular Pharmacology. 67: 1268-1282.
191. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. (2002). Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrobial Agents and Chemotherapy. 46: 1896-1905.
192. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. (2003). Antibody neutralization and escape by HIV-1. Nature. 422: 307-312.
193. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. (1997). Atomic structure of the ectodomain from HIV-1 gp41. Nature. 387: 426-430.
194. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, Borsetti A, Cardoso AA, Desjardin E, Newman W, Gerard C, Sodroski J. (1996). CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature. 384: 179-183.
195. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, Sodroski J. (1995). Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. Journal of Virology. 69: 5723-5733.
196. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, Sodroski JG. (1998). The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 393: 705-711.
197. Wyatt R, Sodroski J. (1998). The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science. 280: 1884-1888.
198. Xu L, Pozniak A, Wildfire A, Stanfield-Oakley SA, Mosier SM, Ratcliffe D, Workman J, Joall A, Myers R, Smit E, Cane PA, Greenberg ML, Pillay D. (2005). Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrobial Agents and Chemotherapy. 49: 1113-1119.
199. Yuan W, Craig S, Si Z, Farzan M, Sodroski J. (2004). CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor. Journal of Virology. 78: 5448-5457.
200. Zhao Q, Ernst JT, Hamilton AD, Debnath AK, Jiang S. (2002). XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41. AIDS Research and Human Retroviruses. 18: 989-997.
201. Zhu P, Olson WC, Roux KH. (2001). Structural flexibility and functional valence of CD4-IgG2 (PRO 542): potential for cross-linking human immunodeficiency virus type 1 envelope spikes. Journal of Virology. 75: 6682-6686.
202. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD. (1993). Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science. 261: 1179-1181.
203. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. (1998). Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 393: 595-599.